Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026)
Zevra Therapeutics (ZVRA) posted Exchange Rate Effect of $233000.0 for Q1 2026, up 172.36% on a QoQ basis from -$322000.0 in Q4 2025, and up 162.63% year-over-year from $88716.5 in Q1 2025.
Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Zevra Therapeutics' Exchange Rate Effect history runs 5 years deep, the most recent figure standing at $233000.0 for Q1 2026.
- Quarterly Exchange Rate Effect rose 162.63% year-over-year to $233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $633000.0 (up 398.43% YoY) and the FY2025 annual result came in at $28000.0, down 93.83% from the prior year.
- Exchange Rate Effect was $233000.0 for Q1 2026 at Zevra Therapeutics, up from -$322000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $671000.0 in Q4 2024 and bottomed at -$491000.0 in Q3 2024.
- A 5-year average of $64200.0 and a median of $64000.0 in 2025 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2023 — Exchange Rate Effect plunged 780.0% — and 2024, when it jumped 219.03%.
- Zevra Therapeutics' Exchange Rate Effect stood at $189000.0 in 2022, then soared by 84.66% to $349000.0 in 2023, then soared by 92.26% to $671000.0 in 2024, then slumped by 147.99% to -$322000.0 in 2025, then soared by 172.36% to $233000.0 in 2026.
- Business Quant data shows ZVRA's Exchange Rate Effect at $233000.0 in Q1 2026, -$322000.0 in Q4 2025, and $64000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 619,347.27 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 19.32 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 14,631.83 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -40.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -900,000.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 233,000.00 |
| Mar 31, 2026 | 233,000.00 |
| Dec 31, 2025 | -322,000.00 |
| Dec 31, 2025 | -322,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Mar 31, 2025 | -372,000.00 |
| Mar 31, 2025 | -372,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Sep 30, 2024 | -491,000.00 |
| Sep 30, 2024 | -491,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | 349,000.00 |
| Dec 31, 2023 | 349,000.00 |